Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome - Concepedia

Concepedia

Publication | Open Access

Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome

DOI Full Paper Access

72

Citations

53

References

2005

Year

Nicholas A. Cataldo, Fahim Abbasi, Tracey McLaughlin, Marina Basina, Patricia Y. Fechner, Linda C. Giudice, Gerald M. Reaven

Human Reproduction

Abstract

Rosiglitazone in insulin-resistant PCOS promoted ovulation and dose-dependently decreased IR and insulinaemia; ovulators had lower circulating insulin and testosterone.

References

	Year	Citations

Page 1